DSK, Last Year's Sales 49.6 Billion KRW... 52% Increase YoY
[Asia Economy Reporter Hyungsoo Park] DSK announced on the 28th that its consolidated sales last year reached 49.6 billion KRW, a 52% increase compared to the same period of the previous year.
A company official explained, "Orders increased due to expanded facility investments in front-end industries such as organic light-emitting diode (OLED) and secondary batteries," adding, "Sales from new equipment businesses, including mobile camera module equipment, were also reflected."
He continued, "However, a consolidated operating loss of 6.4 billion KRW occurred due to clinical costs of Protox, a botulinum toxin bio-specialized subsidiary, but the deficit size decreased compared to the previous year."
On a separate basis, DSK's sales amounted to 48.9 billion KRW, a 52.6% increase compared to the same period last year. Operating profit turned positive to 2.87 billion KRW.
DSK is developing various automation equipment such as OLED display equipment, secondary batteries, mobile camera modules, and lasers based on its differentiated precision system equipment manufacturing capabilities.
A DSK official said, "Last year, facility investments continued across all industries we entered, including displays and mobile cameras, achieving solid performance evenly in both existing and new equipment businesses."
He added, "Thanks to the performance of the equipment business, we succeeded in turning a profit on a separate basis last year," and "Since Protox signed an exclusive local supply and joint clinical contract with a pharmaceutical and bio-specialized company in China at the end of last year, we will focus our capabilities on delivering meaningful results this year."
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Protox, DSK's bio-specialized subsidiary, is researching and developing Protoxins, a botulinum toxin type A formulation based on its own strains. Protox signed a contract with a local pharmaceutical and bio company in China in December last year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.